Japan: PMDA Approval and National Health Insurance Coverage
Japan's Pharmaceuticals and Medical Devices Agency reviews GLP-1 drugs under its own process, with coverage tied to the country's universal National Health Insurance system.
By the GLP Semaglutide editorial team · Last updated February 25, 2026
Japan's Pharmaceuticals and Medical Devices Agency (PMDA), working with the Ministry of Health, Labour and Welfare, reviews and approves drugs for the Japanese market, including GLP-1 receptor agonists for their respective approved indications.
Universal coverage changes the access picture
Japan's National Health Insurance system covers approved medications for approved indications for enrolled residents, with government-set pricing — a structurally different affordability model than the U.S. employer/private-insurance system, though coverage for weight-management-specific use has its own eligibility criteria.
Where to verify
PMDA's English-language site publishes approval information, and Japan's health ministry sets and publishes NHI coverage and pricing decisions directly.
Primary sources